ArticleFrontiers in pharmacology2025
Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ischemic Heart Disease (IHD) represents one of the major causes of mortality and morbidity in the geriatric population This clinical complexity of these patients substantially impacts their quality of life and is associated with an increased risk of cognitive impairment (CoI). Ranolazine, plays a pivotal role in managing anginal symptoms and improving exercise tolerance. Objective: To investigate the potential protective effect of Ranolazine on CoI over time in elderly patients with IHD and multiple comorbidities. Methods: We performed a single-center, prospective, observational cohort study. The primary endpoint was a reduction in MMSE score ≥3 points during follow-up compared to baseline values. Results: 519 patients with a mean age of 74.2 ± 6.8 years were enrolled and divided into two groups based on Ranolazine use. The groups demonstrated comparable distribution by sex; however, Ranolazine group, although younger, displayed increased severity of anginal symptoms (Canadian Angina Scale 2.6 vs. 2.3; p < 0.0001), higher prevalence of previous acute coronary syndrome (p < 0.046), sarcopenia (p < 0.0001), and type 2 diabetes mellitus (p < 0.040). During a 4-year follow-up, 186 cases of CoI were observed (8.9 events/100 patient-years) in the general population. The incidence of CoI was significantly lower in the Ranolazine group compared to the control group (5.7 vs. 10.3 events/100 patient-years; p < 0.001). Multivariate analysis revealed a statistically significant association between CoI and the use of Ranolazine, GLP-1RAs, and SGLT2i. Specifically, Ranolazine use was associated with a 61% odds reduction in CoI. Conclusion: The use of Ranolazine is associated with a significant odds reduction in CoI in elderly patients with IHD and multiple comorbidities. The neuroprotective effect of Ranolazine may be attributed to the improvement of anginal symptoms and consequent optimization of functional status and quality of life, advocating for a comprehensive therapeutic strategy in geriatric patient management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.